Idorsia's Aprocitentan Shows Strong Efficacy in Obesity and Cardiometabolic Patients
Event summary
- Idorsia presented data at AHA Hypertension 2026 showing aprocitentan reduced blood pressure by 15-16 mmHg in obese patients and those across the cardiovascular-kidney-metabolic (CKM) continuum.
- The drug also demonstrated kidney protective effects, with a 50% reduction in UACR and stable eGFR in CKM patients.
- PRECISION study post-hoc analyses involved 506 obese patients and 683 CKM patients (stages 2 and 4a).
- Aprocitentan is approved as TRYVIO in the US and JERAYGO in Europe for resistant hypertension.
- The findings reinforce the role of endothelin pathway blockade in difficult-to-control hypertension.
The big picture
Idorsia's findings position aprocitentan as a potential game-changer in treating resistant hypertension, particularly in high-risk populations like obese patients and those with cardiovascular-kidney-metabolic disease. The data supports the growing recognition of the endothelin pathway as a critical target in hypertension management. With 1.4 billion people worldwide living with hypertension and many failing to achieve adequate control, aprocitentan could address a significant unmet medical need.
What we're watching
- Therapeutic Differentiation
- Whether aprocitentan's endothelin pathway blockade can establish it as a distinct treatment option beyond existing hypertension therapies.
- Regulatory Expansion
- The pace at which Idorsia can secure additional approvals for aprocitentan in broader patient populations.
- Commercial Strategy
- How Idorsia will position aprocitentan against competitors in the growing market for resistant hypertension treatments.
Related topics
